- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02132897
Fed Bioequivalence Study of CBZ Formulations
Fed Bioequivalence Study of Carbamazepine Controlled Release Formulations in Healthy Male Uruguayan Subjects
Controlled release Carbamazepine (CBZ) is a antiepileptic, antineuralgic and mood stabilizer drug. The CR formulation of CBZ is slowly absorbed and the elimination half life varies with time due to metabolism autoinduction.
The primary objective of this study is to estimate the bioequivalence of the new brand generic product (Auration(R) CR) 400 mg manufactured in Uruguay vs. the innovative product (Tegretol(R) CR) 400 mg manufactured in Brasil, under fed conditions. The secondary objective will be evaluation of safety issues.
The study design will be randomized two sequences, two periods and crossover. For a power of not less than 80% sample size was estimated to be 20 healthy male subjects. Products will be administered with food (high calories/high fat breakfast) after an overnight fast.
Time vs. concentration curves will be built for each subject and formulation and Area Under Curve (AUC0240) will be estimated using the trapezoid rule, the AUC 0-inf. (from time 0 to infinity) will be estimated using the formula Cz/Ke, Cmax will be taken from the individual curves.
This parameters will be statistically processed with the WinNonlin 6.3 Pharmacokinetics/Statistic software in order to prove bioequivalence between the study products.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Montevideo, Uruguay, 11800
- Center for Clinical Pharmacology Research Bdbeq S.A. Italian Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-smoking or smokers of less than 5 cigarettes/day, within the age range of 18 to 50 years.
- Body Mass Index (BMI = weight/height2) greater than or equal to 18.5 kg/m2 and less than or equal to 24.9 kg/m2.
- No clinically significant findings in the physical examination, 12-lead electrocardiogram (ECG) and vital signs (blood pressure between 100-140/58-90 mmHg, heart rate between 50-99 beats/min, temperature between 35.8ºC and 37.6ºC, respiration rate between 12 and 20 breaths/minute)
- No clinical laboratory values outside of the acceptable range as per protocol, unless the Principal Investigator or Sub-investigator decides that they are not clinically significant (NCS).
- Availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements.
- The subject agrees to abstain from alcohol, coffee and other food and drinks containing methylxanthines (mate, tea, cola, chocolate) for 48hours, and grapefruit containing food and beverages for 72 hours prior study drug administration and during each study period.
Exclusion Criteria:
- Known history of hypersensitivity to Carbamazepine and/or related drugs.
- Positive test for hepatitis B surface antigen, hepatitis C or HIV.
- Known history of gastrointestinal (e.g: gastritis, inflammatory bowel disease, celiac disease), cardiac, pulmonary, endocrine, musculoskeletal, neurological, hematological, immunological, hepatic or renal disease, or malignancies, unless deemed NCS by the Principal Investigator or Sub-investigator.
- Any history of peptic ulcer disease or gastrointestinal (GI) bleeding.
- Any history of gastrointestinal surgery (except for appendectomy).
- Presence of any significant physical or organ abnormality.
- Any illness during the 4 weeks before this study, unless deemed NCS by the Clinical Investigator or Sub-investigator.
- Any history or evidence of psychiatric or psychological disease, unless deemed NCS by the Clinical Investigator or Sub-investigator.
- Any history of asthma (after 12 years of age).
- Any history of severe allergic reaction (including drugs, food, insect bites, environmental allergens).
- Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
- Any history of drug and psychoactive medicines abuse.
- Any recent history of alcohol abuse (less than 1 year).
- Use of any prescription medication within 14 days preceding this study.
- Use of vaccinations within 30 days preceding this study.
- Use of over-the-counter (OTC) medication within the 7 days preceding this study (except for spermicidal/barrier contraceptive products, sunscreen and sunblock products).
- Participation as a plasma donor in a plasmapheresis program within 7 days preceding this study.
- Blood donations within 60 days preceding and after this study.
- Participation in a clinical trial with an investigational drug within 180 days preceding this study, and agreement not to participate in a clinical trial for 180 days after this study.
- Intolerance to venipuncture.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: TR (Test - Reference)
Sequence : Auration CR 400 Single Dose/Tegretol CR 400 Single Dose
|
Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.
Other Names:
|
Other: RT (Reference - Test)
Sequence: Tegretol CR 400 Single Dose/Auration CR 400 Single Dose
|
Auration CR 400 milligrams Single Dose is given orally with 250 mL of water at room temperature.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC0-240
Time Frame: 10 days
|
Area Under the CBZ Concentration vs. time curve from sample time point 0 hour to sample time point 240 hour.
|
10 days
|
AUC0-inf
Time Frame: 0 to 240 hours
|
Area Under the CBZ Concentrations vs, time curve from sample time point 0 hour to sample time point 240 hours plus extrapolation to infinity of the terminal concentration slope.
|
0 to 240 hours
|
Cmax
Time Frame: 12 to 48 hours
|
The maximum concentration in the CBZ concentrations vs. time curves for each subject and each formulation.
|
12 to 48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AE
Time Frame: 31 days
|
Recording of all adverse events (AE) occurring during the study: expected, unexpected and serious (SAE) from tree different sources.
The AEs may be clinical occurrences, abnormal labs or ECG alterations.
|
31 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax
Time Frame: 12 to 48 hours
|
Time from 0 concentration sample point to the Cmax sample point.
|
12 to 48 hours
|
Ke
Time Frame: From 48 to 240 hours
|
The constant rate of elimination (Ke) is the slope of the terminal phase of the CBZ concentration vs. time curve.
|
From 48 to 240 hours
|
T1/2e
Time Frame: 48 to 240 hours
|
It is the time that CBZ concentration, in the elimination (terminal) phase, fall off by half.
|
48 to 240 hours
|
Vital signs
Time Frame: 20 days
|
Measuring of blood pressure, heart rate, body temperature and ventilation rate.
|
20 days
|
Admission and discharge screening
Time Frame: 21 days
|
Laboratory analysis and ECG performed prior to admission to the clinic and prior to discharge from the study.
|
21 days
|
Collaborators and Investigators
Investigators
- Study Director: Francisco E. Estevez-Carrizo, M.D., Center for Clinical Pharmacology Research Bdbeq S.A.
- Principal Investigator: Francisco T. Estevez-Parrillo, M.D., Center for Clinical Pharmacology Research Bdbeq S.A.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Anticonvulsants
- Sodium Channel Blockers
- Antimanic Agents
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Carbamazepine
Other Study ID Numbers
- BDBEQ-CBZ400/EUFUY-023
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bio-equivalence Study
-
BayerCompleted
-
Rambam Health Care CampusCompletedBio-Oss; MucograftIsrael
-
University of AberdeenKellogg CompanyCompletedBio-availability of Wheat Bran Phytochemicals in the Human Gut | Bio-availability of Wheat Bran Phytochemicals for the Systemic CirculationUnited Kingdom
-
Avidhrt Inc.Michigan State University; ASCENSION SACRED HEART; Spring Arbor UniversityNot yet recruitingEquivalence of ECG Electrode Type Signal Quality for AF and Non AF Users
-
Anemia Working Group RomaniaDr Carol Davila Teaching Hospital of Nephrology; Romanian Renal RegistryWithdrawnBio-Equivalency of 2 Treatment Schedules in HD PatientsRomania
-
UCB Biopharma S.P.R.L.CompletedElderly Study Participants | Adult Study ParticipantsUnited States
-
Mondelēz International, Inc.Reading Scientific Services Ltd.WithdrawnStudy Focus 1:Glycaemic Index | Study Focus 2:Glycaemic Response | Study Focus 3:Insulinemic ResponseUnited Kingdom
-
Shanghai Mental Health CenterWest China Hospital; Wuhan Mental Health Centre; Second Xiangya Hospital of Central... and other collaboratorsCompletedBcenzodiazepines, Abuse, Retrospective Study, Focus Groups, Real-world StudyChina
-
National Cancer Institute (NCI)CompletedValidation Study | Diet Surveys | Nutritional Assessment | Epidemiology | Methodologic StudyUnited States
-
University of ZurichETH Zurich, Human Nutrition LaboratoryCompletedStudy Not Related to a Disease. Nutrition Study Without Drug Administration.Switzerland
Clinical Trials on Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose
-
Contrad Swiss SACompleted
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unknown
-
Yuhan CorporationCompleted
-
Actavis Inc.Completed
-
Actavis Inc.Completed
-
Actavis Inc.Completed
-
Actavis Inc.Completed
-
Actavis Inc.Completed
-
Actavis Inc.Completed
-
Medicines for Malaria VentureCompleted